The draining lymph nodes of carcinoma tissues are exposed to metastatic cancer cells. degradation products or materials secreted by the main tumour via lymphangitic vessels. This suggests the existence of an in situ immune response against tumour-associated antigens. and. in fact. regional nodal lymphocytes have been a suitable source of fusion parents in producing tumour-reactive human monoclonal antibodies (Cole et al. 1984 : Glassy. 1987 : Kjeldsen et al. 1988 : Inoue et al. 1989 : Pfaff et al. 1990 : Miyake et al. 1992 ). Both practical and theoretical uses and limitations of using lymphocytes isolated from regional draining, lymph nodes of cancer patients have been discussed (Glassy and McKnight. 1994: McKnight and Glassy. 1995) . However. although insights into the human immune response to cancer antigens have been obtained from these analyses. little is known as to the physiological role of these auto-tumour-reactive antibodies in carcinoma-bearing patients. The fact that cancers do grow suggests that the antibody andlor other components that normally function properly failed to do so. In addition to the inhibition of cancer cell expansion. there is a possibility that these antibodies may reduce cell-mediated cytotoxicity by masking the target antigens for effector cells. Detenmining this issue is essential when considering specific cancer biotherapy using HuMAbs or cancer vaccines. In the current studv. we characterized a human natural antibody to adenocarcinoma and investigated the biological role of this Ag/Ab complex in cancer expansion. In addition. we discussed the future potential of immunotherapy using this human antibdy.
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MATERIALS AND METHODS

Cell lines
Carcinoma cell lines were all purchased from ATCC (Rockville. MD. USA). A human lymphoblastoid cell line fusion partner. sHFP-1. was grown and used as described previously (Glassy. 1989 ).
Hybridoma generation
Eighteen regional draining lymph nodes from six Dukes' B colon carcinoma patients were taken aseptically from resected specimens. Nodal lymphocvtes were prepared as a single-cell suspension by mechanical dispersion with scalpels as described prex iously (Glassy. 1987) . Approximately 5.0 x 10 to 1.0 x 10-lymphocytes from each lymph node were individually stimulated w-ith a cytokine mixture (Borrebaeck et al. 1988 ) for 6-7 davs following an 'in vitro stimulation' procedure 
Invasion assay
The invasion capacity of colon carcinoma cell lines was determined using a 24-well microchemotaxis chamber (Kurashiki Boseki, Okayama. Japan) in quadruplicate assay (Aznavoorian et al, 1990) . A polycarbonate membrane with an 8-jm pore size was precoated with an extracellular matrix mixture in D-PBS (40 jg ml-' of type 4 collagen. 10 jg ml-' fibronectin and 5 jg ml-' laminin. all from Cosmo Bio. Tokyo. Japan) by soaking overnight in this mixture at 4°C. After removal of the solution. RPMI-1640 supplemented with 10% fetal calf serum (FCS) was added to the unit. In the upper chamber, I0W cells per well were seeded, whereas, in the lower chamber, 5 jg ml-' laminin. fibronectin and type 4 collagen were added as chemoattractants. After 36 h of incubation at 37°C in a 5% carbon dioxide humidified incubator, the membranes were fixed with cold acetone for 8 min and stained with Meyer's haematoxylin. The number of cells that migrated to the lower side of the membrane was microscopically counted and evaluated. In some experiments either purified HuMAb SKI or irrelevant human IgM MAb was added to the upper chamber at various concentrations to inhibit the cell migration with antibodies.
Immunohistochemical staining A panel of frozen sections (4 jm thick) of human tissues was stained with HuMAb SKI using a standard avidin-biotin peroxidase complex (ABC) method. When deparaffinized formalin-fixed sections were used, they were soaked in 0.1 M citrate buffer (pH 6.0) and treated with microwaves twice for 10 min as described previously (Shi et al, 1991; van den Berg et al. 1993 ).
Frozen sections were fixed with cold acetone for 8 min before the blocking procedures. Sections were first treated with 0.03% hydrogen peroxidase in methanol for 30 min, washed, then blocked with 1% BSAID-PBS plus 5 jg ml' of goat anti-human IgM (Jackson lmmunoResearch) at room temperature for 1 h.
After washing with D-PBS, HuMAb SKI diluted to 5 jg ml-' with 0.5% BSA/D-PBS was applied and incubated overnight in the moist chamber at 4°C. After washing. the sections were incubated with biotinylated goat anti-human IgM (Jackson ImmunoResearch) for 1 h at room temperature. They were then washed and incubated with avidin-biotinylated peroxidase complex (ABC staining kit from Dako Japan. Tokyo, Japan) for I h at room temperature. After several more washings, slides were reacted with diaminobenzidine substrate for 10 min. rinsed, counterstained with haematoxylin and mounted.
Flow cytometry Single cell suspensions of colon carcinoma cell lines were treated with 3.7% formaldehyde solution for 10 min at room temperature. After removal of the solution, cold acetone was added and incubated on ice for 5 min. washed, then incubated in 5% FCS/D-PBS for 1 h. Following washings. SKI or human polyclonal IgM (each at 5 jg ml-'), was applied and incubated on a shaker for 1 h at room temperature. washed. then appropriately diluted FITCconjugated goat anti-human IgM (Jackson ImmunoResearch) was added and incubated for an additional 30 min at room temperature.
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After washina. they were passed through a nylon mesh (200 inch-' mesh). stained with propidium iodide (PI: 20 jgc ml-'. Siama) and then analysed with FACScan (Becton Dickinson Japan. Tokyo. Japan with these antibodies showed that most of the selected HuMAbs were not specific to carcinoma but were multi-reactive. even to non-malignant cells ). Among these HuMAbs.
SKI showed the most restricted specificity to carcinoma cell lines (Chang, et al. 1993 ). This carcinoma-preferred reactivits A as confirmed by immunohistochemical study in which SKI reacted mainly Awith malignant tissues originating in the epithelium ( proliferation or cell density. This is shown in Figure 3 . Figure 3A shows the degree on immunostaining by individual cells. and 3B shows a small colony. The outer peripheral region. typically a threeto five-cell-thick layer. of a larger colony of cells ( Figure 3C and D Figure 4 . Calu-1 cells were seeded at low density ( Figure  4 . ID) and allowed to expand until the cultures were greater than 90% confluent. typically by days 6-7. As can be seen. the antigen is diffuse and spread throughout the cell in very low-density cultures. By day 3. the antigen has rounded up' and can be seen indenting the nucleus. High-density cultures were Ag-SKl negative by immunostaining. Similar findings were also observed in PANC-1. pancreatic cancer cells (data not shown). These data suggest that Ag-SKl is not always expressed on a given carcinoma cell but is metabolized in each cell depending on the circumstances. Two-colour FACS analysis using HuMAb SKI and PI showed that antigen expression in each cell is independent of the cell cycle status ( Figure 5 ).
Dot-blot analysis
The amount of Ag-SKl per extracted cell protein was assessed by dot-blot analysis ( Figure 6 . Table 2 ). where the ratio of Ag-SKIpositive cells was deternined by FACS analysis (Table 2) . We showed that the concentration of Ag-SK 1 per protein differs considerably among cell lines. in which SW620. WiDr and LoVo cell lines were considered to express a high amount of Ag-SKL. with the low expression group consisting of Caco-2 and NCI-H716 cell lines.
The data shown in Figure 6 were obtained from cells harvested dunrng mid-log growth (between 30% and 50% confluent. usually 3-4 days' culture) when antigen expression was highest.
In FACS analysis. the antigen-positive cells within each cell line were recorded as a discrete subset with more than ten times greater antigen expression in comparison with the negative cells ( Figure  SB) . (Table 2) . To confirm the hypothesis that A-SKI was an invasion-or a migration-related molecule of colon carcinomas. we next investigated whether the invasion capacity of these cells was inhibited bv the addition of HuMAb SKl into the upper sides of the chemotaxis chambers in a quadruplicate assay. As shown in Figure 7 . 
DISCUSSION
Data have been accumulating indicating that the overall immune system of cancer-bearing patients is able to recognize autologous tumour antigens specifically. In cellular immunity, the cytotoxic T lymphocyte that specifically targets autologous tumours has been induced in vitro (Barnd et al, 1989; Wright et al. 1989; Topalian et al, 1989; Peoples et al, 1995) . In humoral immunity, human monoclonal antibodies against cancers have been primarily generated via hybridoma technology using B lymphocytes from cancerbearing patients (Yamaguchi et al, 1990; Posner et al, 1991; Hoon et al, 1993; Oka et al, 1994) . In spite of the existence of this specific cancer recognition by the patient's immune system. tumours do grow in a physiological environment, implying that the humoral response was an insufficient contribution to the antitumour effect. The basic strategy of cancer biotherapy is to magnify or to modify the innate anti-tumour immune system using a variety of 'bioweapons' such as cytokines Weiner et al, 1991; Dillman et al, 1993; Ernstoff 1994) . gene transfer (Porgador et al, 1993; Tohmatsu et al. 1993 : Iwanuma et al, 1995 , adoptive transfer of activated killer cells (Rosenberg et al, 1986; Andreesen et al, 1990; Keilholz et al. 1994 ) and cancer vaccinations (Elliott et al. 1993; Hoover et al, 1993; Houghton. 1995) . So far, the majority of these approaches have involved cellular immunity, whereas human antibodies have been used in in vivo diagnosis of malignancies only (Ditzel et al. 1993 : Chaudhuri et al, 1994 Ditzel et al, 1994) .
The expected anti-tumour effects of human monoclonal antibodies could be listed as follows: (1) to bind the functional molecule in the metastasizing process of cancer cells, such as invasion. destroying basal membrane, or implantation in distant organs. thereby blocking the cancer metastases or expansions: (2) to induce antibody-dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytolysis (CDC) against cancer cells: and (3) to induce anti-idiotypic antibody against the administered HuMAbs. This second antibody may mimic the tumour-associated antigen(s) and offer an opportunity to induce a cell-mediated immune response specific to tumour cells (Ferrone 1993 : Fargerberg et al. 1995 .
The current data indicate that the antigen that is recognized by HuMAb SKI is a two-chain molecule with approximate molecular weight of 42-46 kDa, as it appears from the two most prominent bands (Figure 2 ). Tissue specificity analysis showed that HuMAb SKI preferentially stained adenocarcinoma tissues with minimal to negative staining among non-epithelial tumours and normal epithelium ( Table 1 ). The antigen-positive cells within each colon cancer cell line seemed to represent a discrete subset with different levels of Ag expression, judging from FACS analysis ( Figure 5 ) and from the immunocytochemical staining of HT-29 (Figure 3) . There was a variety of Ag-positive ratios observed, depending upon the harvested time of the cells (FACS data from ). A HuMAb SKI is considered to be an augmentation of the natural humoral immune response of cancer-bearing patients. It may encourage successful cancer biotherapy using such HuMAbs that exert a direct action upon cancer invasion and metastases. Although the appearance of SKI was low in frequency (1 out of 1036). its existence does suggest that there may be others also specific to cancer. The task then is to develop appropriate search protocols to prove effectively the entire human immune response repertoire and identify those sequences that identify cancerspecific antigens.
The availability of immunoreagents such as SKI will not only provide new insights into the working of the anti-cancer human immune response but also give the oncologist clinically useful antibodies for better diagnosis and therapy. ABBREVIATIONS Ag. antigen: HuMAb. human monoclonal antibody: kDa. kilodalton: HRP. horseradish peroxidase: EIA. enzyme immunoassay: PI. propidium iodide: SDS-PAGE. sodium dodecyl sulphate-polyacrylamide gel electrophoresis: FACS. fluorescence-activated cell sorter.
